Search Results - "Dingemans, A"

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Dingemans, A.-M.C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L.E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C.M., De Ruysscher, D., Van Schil, P.E., Vansteenkiste, J., Reck, M.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing small-cell lung cancer (SCLC).•It covers clinical and pathological diagnosis,…”
Get full text

Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study by Hendriks, L.E, Derks, J.L, Postmus, P.E, Damhuis, R.A, Houben, R.M.A, Troost, E.G.C, Hochstenbag, M.M, Smit, E.F, Dingemans, A.-M.C

“…Highlights • OS significantly longer in single organ metastatic disease compared to 2 or ⩾3 organs. • Single organ metastases also prognostic in subgroup of18…”
Get full text

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial by Remon, J., Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Bernabe, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., Cousin, S., Garrido, P., Robinet, G., Garcia Campelo, R., Madroszyk, A., Mazières, J., Curcio, H., Wasąg, B., Pretzenbacher, Y., Fournier, B., Dingemans, A.-M.C., Dziadziuszko, R.

“…The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing…”
Get full text

EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? by Hendriks, L.E.L, Smit, E.F, Vosse, B.A.H, Mellema, W.W, Heideman, D.A.M, Bootsma, G.P, Westenend, M, Pitz, C, de Vries, G.J, Houben, R, Grünberg, K, Bendek, M, Speel, E.-J.M, Dingemans, A.-M.C

“…Abstract Objectives Both bone and brain are frequent sites of metastasis in non-small cell lung cancer (NSCLC). Conflicting data exist whether EGFR mutant (+)…”
Get full text

Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study by De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, M., Dingemans, A.-M. C., Bootsma, G., Geraedts, W., Simons, J., Pitz, C., Lambin, P.

“…Background: Patients with stage III non-small-cell lung cancer (NSCLC) and limited disease small-cell lung cancer are excluded from concurrent chemoradiation…”
Get full text

Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer? by de Jong, E.E.C., Sanders, K.J.C., Deist, T.M., van Elmpt, W., Jochems, A., van Timmeren, J.E., Leijenaar, R.T.H., Degens, J.H.R.J., Schols, A.M.W.J., Dingemans, A.-M.C., Lambin, P.

“…Muscle depletion negatively impacts treatment efficacy and survival rates in cancer. Prevention and timely treatment of muscle loss require prediction of…”
Get full text

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective by de Joode, K., Dumoulin, D.W., Engelen, V., Bloemendal, H.J., Verheij, M., van Laarhoven, H.W.M., Dingemans, I.H., Dingemans, A.C., van der Veldt, A.A.M.

“…The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of…”
Get full text

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer by van der Wekken, A J, Pelgrim, R, 't Hart, N, Werner, N, Mastik, M F, Hendriks, L, van der Heijden, E H F M, Looijen-Salamon, M, de Langen, A J, Staal-van den Brekel, J, Riemersma, S, van den Borne, B E, Speel, E J M, Dingemans, A-M C, Hiltermann, T J N, van den Berg, A, Timens, W, Schuuring, E, Groen, H J M

“…ALK rearrangement detection using FISH is the standard test to identify patients with non-small cell lung carcinoma (NSCLC) eligible for treatment with ALK…”
Get full text

The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer by Degens, J.H.R.J., Sanders, K.J.C., de Jong, E.E.C., Groen, H.J.M., Smit, E.F., Aerts, J.G., Schols, A.M.W.J., Dingemans, A.-M.C.

“…•SM, SAT and RA decrease significantly after two lines of chemotherapy.•Low SM index at baseline does not significantly influence OS.•Loss of SM after two…”
Get full text

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC) by Hermans, B.C.M., Derks, J.L., Thunnissen, E., van Suylen, R.J., den Bakker, M.A., Groen, H.J.M., Smit, E.F., Damhuis, R.A., van den Broek, E.C., Stallinga, C.M., Roemen, G.M., Speel, E.J.M., Dingemans, A.-M.C.

“…•PD-L1 ≥ 1% is expressed in 16% of stage IV LCNEC, 5% has expression ≥50%.•PD-L1 staining in LCNEC is comparable to values in SCLC, but lower than in NSCLC.•No…”
Get full text

Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer by Kuijpers, C.C.H.J., Hendriks, L.E.L., Derks, J.L., Dingemans, A-M.C., van Lindert, A.S.R., van den Heuvel, M.M., Damhuis, R.A., Willems, S.M.

“…•NSCLC molecular status was associated with metastatic pattern at diagnosis.•EGFR+ tumors more often bone and pleural metastases than triple-negative.•EGFR+…”
Get full text

Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature by Hermans, B.C.M., Derks, J.L., Moonen, L., Habraken, C.H.J., der Thüsen, J. von, Hillen, L.M., Speel, E.J.M., Dingemans, A-M.C.

“…•Carcinoids are characterized by well differentiated morphology and low proliferation.•LCNEC is characterized by poorly differentiated morphology and high…”
Get full text

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study by AERTS, J. G, CODRINGTON, H, LANKHEET, N. A. G, BURGERS, S, BIESMA, B, DINGEMANS, A. -M. C, VINCENT, A. D, DALESIO, O, GROEN, H. J. M, SMIT, E. F

“…Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered concurrently with chemotherapy did not improve outcome in non-small-cell lung…”
Get full text

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer by Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M.J., Arcila, M.E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A.M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Jänne, P.A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I.I., Wolf, J., Wu, Y.L., Yang, S.R., Yang, J.C.H., Yatabe, Y., Pentheroudakis, G., Peters, S.

“…The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell…”
Get full text

Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not? by Xander, N.S.H., Leeneman, B., Dingemans, A.-M.C., Fiets, W.E., de Jong, W.K., Uyl, N.E.M., Wymenga, A.N.M., Reyners, A.K.L., Uyl-de Groot, C.A.

“…The Dutch Committee for the Evaluation of Oncological Agents (cieBOM) assesses the clinical benefit of systemic anti-cancer treatments (SACTs). For SACTs…”
Get full text

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer by Pruis, M.A., Geurts-Giele, W.R.R., von der, Thüsen J.H., Meijssen, I.C., Dinjens, W.N.M., Aerts, J.G.J.V., Dingemans, A.M.C., Lolkema, M.P., Paats, M.S., Dubbink, H.J.

“…•MET exon 14 skipping mutations in lung cancer can be reliably detected in DNA.•2 % of the non-squamous NSCLC is driven by a MET exon 14 skipping…”
Get full text

Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study by Witlox, W.J.A., Ramaekers, B.L.T., Joore, M.A., Dingemans, A.-M.C., Praag, J., Belderbos, J., Tissing-Tan, C., Herder, G., Haitjema, T., Ubbels, J.F., Lagerwaard, J., El Sharouni, S.Y., Stigt, J.A., Smit, E.F., van Tinteren, H., van der Noort, V., Groen, H.J.M., De Ruysscher, D.K.M.

“…•Scores of the HRQoL metrics were not different between PCI and observation.•HRQoL was lower in patients with neurocognitive symptoms and BM.•The utility score…”
Get full text

Normative data for the lower extremity functional scale (LEFS) by Dingemans, Siem A, Kleipool, Suzanne C, Mulders, Marjolein A M, Winkelhagen, Jasper, Schep, Niels W L, Goslings, J Carel, Schepers, Tim

“…Background and purpose - The lower extremity functional scale (LEFS) is a well-known and validated instrument for measurement of lower extremity function. The…”
Get full text

DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile by Hermans, B.C.M., Derks, J.L., Thunnissen, E., van Suylen, R.J., den Bakker, M.A., Groen, H.J.M., Smit, E.F., Damhuis, R.A., van den Broek, E.C., Ruland, A., Speel, E.J.M., Dingemans, A.M.C.

“…•DLL3 is expressed in 74% of stage IV LCNEC patients•The majority (80%) has cytoplasmic/membranous expression•DLL3 is expressed in both SCLC- and NSCLC-like…”
Get full text

Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: Exploring the model-based approach by Aldenhoven, Loeki, Ramaekers, B., Degens, J., Oberije, C., van Loon, J., Dingemans, A.C., De Ruysscher, D., Joore, M.

“…•Patient selection for whom PT is expected to be beneficial is crucial.•Normal tissue complication probability models are important for patient…”
Get full text